The use of quinacrine (Atabrine) in rheumatic diseases: A reexamination
Identifieur interne : 003111 ( Main/Exploration ); précédent : 003110; suivant : 003112The use of quinacrine (Atabrine) in rheumatic diseases: A reexamination
Auteurs : Daniel J. Wallace [États-Unis]Source :
- Seminars in Arthritis and Rheumatism [ 0049-0172 ] ; 1989.
English descriptors
- Teeft :
- Acad, Acta, Acta physiol acad, Antimalarial, Antimalarial drugs, Antimalarial therapy, Aplastic, Aplastic anemia, Arachidonic acid, Atabrine, Biochem, Biol, Chloroquine, Cyclic, Dermatol, Discoid, Discoid lupus, Discoid lupus erythematosus, Dos, Dubois, Effusion, Erythematosus, Female sterilization, Hydroxychloroquine, Inhibition, Inhibitor, Lancet, Late sequelae, Lupus, Lupus erythematosus, Malignant, Mecaprine, Mepacrine, Pharmacol, Pharmacological basis, Phospholipase, Phospholipase inhibitor, Physiol, Plaquenil, Platelet, Prostaglandin, Quinacrine, Quinacrine hydrochloride, Quinacrine hydrochloride pellets, Quinacrine mustard, Rheumatoid, Rheumatoid arthritis, Surg, Synthetic antimalarials, Systemic lupus erythematosus, Thorac cardiovasc surg, Toxic psychosis, Toxicity.
Abstract
Abstract: Atabrine has been available for nearly 60 years. It has a variety of actions and has been administered to millions of individuals. Its antirheumatic properties have been well documented but have not been exploited optimally for a variety of reasons. The drug is generally quite safe and could be used in low doses in lupus and rheumatoid arthritis patients as a steroid-sparing agent or synergistically with hydroxychloroquine. Its bothersome side effects should not deter the clinician from using it, because they are easy to deal with or prevent (Table 5). Future studies should attempt to better characterize the immunosuppressive actions of this powerful drug, particularly in the treatment of lupus erythematosus and rheumatoid arthritis. Studies of the role of combination or single-agent antimalarial therapy in combination with other “remittive” drugs could be of great potential benefit.
Url:
DOI: 10.1016/0049-0172(89)90050-4
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000072
- to stream Istex, to step Curation: 000072
- to stream Istex, to step Checkpoint: 001E75
- to stream Main, to step Merge: 003180
- to stream Main, to step Curation: 003111
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>The use of quinacrine (Atabrine) in rheumatic diseases: A reexamination</title><author><name sortKey="Wallace, Daniel J" sort="Wallace, Daniel J" uniqKey="Wallace D" first="Daniel J." last="Wallace">Daniel J. Wallace</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7A91CC5BFB6304559D55C10CC8D341A78A24AF12</idno><date when="1989" year="1989">1989</date><idno type="doi">10.1016/0049-0172(89)90050-4</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-MMJVV1PV-F/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000072</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000072</idno><idno type="wicri:Area/Istex/Curation">000072</idno><idno type="wicri:Area/Istex/Checkpoint">001E75</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001E75</idno><idno type="wicri:doubleKey">0049-0172:1989:Wallace D:the:use:of</idno><idno type="wicri:Area/Main/Merge">003180</idno><idno type="wicri:Area/Main/Curation">003111</idno><idno type="wicri:Area/Main/Exploration">003111</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">The use of quinacrine (Atabrine) in rheumatic diseases: A reexamination</title><author><name sortKey="Wallace, Daniel J" sort="Wallace, Daniel J" uniqKey="Wallace D" first="Daniel J." last="Wallace">Daniel J. Wallace</name><affiliation wicri:level="3"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Rheumatology, Department of Medicine, Cedars-Mount Sinai Medical Center, UCLA School of Medicine, Los Angeles</wicri:regionArea><placeName><settlement type="city">Los Angeles</settlement><region type="state">Californie</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Seminars in Arthritis and Rheumatism</title><title level="j" type="abbrev">YSARH</title><idno type="ISSN">0049-0172</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1989">1989</date><biblScope unit="volume">18</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="282">282</biblScope><biblScope unit="page" to="296">296</biblScope></imprint><idno type="ISSN">0049-0172</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0049-0172</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acad</term><term>Acta</term><term>Acta physiol acad</term><term>Antimalarial</term><term>Antimalarial drugs</term><term>Antimalarial therapy</term><term>Aplastic</term><term>Aplastic anemia</term><term>Arachidonic acid</term><term>Atabrine</term><term>Biochem</term><term>Biol</term><term>Chloroquine</term><term>Cyclic</term><term>Dermatol</term><term>Discoid</term><term>Discoid lupus</term><term>Discoid lupus erythematosus</term><term>Dos</term><term>Dubois</term><term>Effusion</term><term>Erythematosus</term><term>Female sterilization</term><term>Hydroxychloroquine</term><term>Inhibition</term><term>Inhibitor</term><term>Lancet</term><term>Late sequelae</term><term>Lupus</term><term>Lupus erythematosus</term><term>Malignant</term><term>Mecaprine</term><term>Mepacrine</term><term>Pharmacol</term><term>Pharmacological basis</term><term>Phospholipase</term><term>Phospholipase inhibitor</term><term>Physiol</term><term>Plaquenil</term><term>Platelet</term><term>Prostaglandin</term><term>Quinacrine</term><term>Quinacrine hydrochloride</term><term>Quinacrine hydrochloride pellets</term><term>Quinacrine mustard</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Surg</term><term>Synthetic antimalarials</term><term>Systemic lupus erythematosus</term><term>Thorac cardiovasc surg</term><term>Toxic psychosis</term><term>Toxicity</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Atabrine has been available for nearly 60 years. It has a variety of actions and has been administered to millions of individuals. Its antirheumatic properties have been well documented but have not been exploited optimally for a variety of reasons. The drug is generally quite safe and could be used in low doses in lupus and rheumatoid arthritis patients as a steroid-sparing agent or synergistically with hydroxychloroquine. Its bothersome side effects should not deter the clinician from using it, because they are easy to deal with or prevent (Table 5). Future studies should attempt to better characterize the immunosuppressive actions of this powerful drug, particularly in the treatment of lupus erythematosus and rheumatoid arthritis. Studies of the role of combination or single-agent antimalarial therapy in combination with other “remittive” drugs could be of great potential benefit.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li></region><settlement><li>Los Angeles</li></settlement></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Wallace, Daniel J" sort="Wallace, Daniel J" uniqKey="Wallace D" first="Daniel J." last="Wallace">Daniel J. Wallace</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003111 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003111 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:7A91CC5BFB6304559D55C10CC8D341A78A24AF12
|texte= The use of quinacrine (Atabrine) in rheumatic diseases: A reexamination
}}
| This area was generated with Dilib version V0.6.33. |  |